Cargando…
XRN2 Is Required for Cell Motility and Invasion in Glioblastomas
One of the major obstacles in treating brain cancers, particularly glioblastoma multiforme, is the occurrence of secondary tumor lesions that arise in areas of the brain and are inoperable while obtaining resistance to current therapeutic agents. Thus, gaining a better understanding of the cellular...
Autores principales: | Dang, Tuyen T., Lerner, Megan, Saunders, Debra, Smith, Nataliya, Gulej, Rafal, Zalles, Michelle, Towner, Rheal A., Morales, Julio C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100175/ https://www.ncbi.nlm.nih.gov/pubmed/35563787 http://dx.doi.org/10.3390/cells11091481 |
Ejemplares similares
-
Novel approaches to combat chemoresistance against glioblastomas
por: Towner, Rheal A., et al.
Publicado: (2020) -
OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma
por: Thomas, Lincy, et al.
Publicado: (2020) -
Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model()()
por: Zalles, Michelle, et al.
Publicado: (2020) -
A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007
por: Zalles, Michelle, et al.
Publicado: (2021) -
Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model
por: Zalles, Michelle, et al.
Publicado: (2019)